# A Study to Evaluate Safety and Efficacy of PBK_M2502

> **NCT07114406** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Pharmbio Korea Co., Ltd.** · enrollment: 110 (estimated)

## Conditions studied

- Intestinal Disease
- Colonic Diseases
- Gastrointestinal Disease
- Digestive System Disease

## Interventions

- **DRUG:** PBK_M2502 1-Day
- **DRUG:** PBK_M2502 2-Day

## Key facts

- **NCT ID:** NCT07114406
- **Lead sponsor:** Pharmbio Korea Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2026-08
- **Final completion:** 2026-11
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07114406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07114406, "A Study to Evaluate Safety and Efficacy of PBK_M2502". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07114406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*